T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | February 2014 |
| End Date: | February 2016 |
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Background:
The NCI Surgery Branch has developed an experimental therapy for treating patients with
melanoma that involves taking white blood cells from the patient, growing them in the
laboratory in large numbers, genetically modifying them, and then giving the cells back to
the patient. In a previous study, the NCI Surgery Branch used the anti-ESO-1 gene and a type
of virus (retrovirus) to make these tumor-fighting cells (anti-ESO-1 cells). About half of
the patients who received this treatment experienced shrinking of their tumors. In this
study, we are using a slightly different method of producing the anti-ESO-1 cells selected
for a specific cell type, which we hope, will be better in making the tumors shrink.
Objectives:
The purpose of this study is to see if these tumor fighting cells (genetically modified
cells) that express the receptor for the ESO-1 molecule on their surface can cause melanoma
tumors to shrink and to see if this treatment is safe.
Eligibility:
-Adults 18 and older with cancer that has the ESO-1 molecule on tumor surfaces
Design:
- Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and
undergo a history and physical examination, scans, x-rays, lab tests, and other tests
as needed
- Leukapheresis: If the patients meet all of the requirements for the study they will
undergo leukapheresis to obtain white blood cells to make the anti ESO-1 cells.
{Leukapheresis is a common procedure, which removes only the white blood cells from the
patient.}
- Treatment: Once their cells have grown, the patients will be admitted to the hospital
for the conditioning chemotherapy, the anti-ESO 1 cells and aldesleukin. They will stay
in the hospital for about 4 weeks for the treatment.
Follow up: Patients will return to the clinic for a physical exam, review of side effects,
lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1
year as long as their tumors are shrinking. Follow up visits take up to 2 days.
The NCI Surgery Branch has developed an experimental therapy for treating patients with
melanoma that involves taking white blood cells from the patient, growing them in the
laboratory in large numbers, genetically modifying them, and then giving the cells back to
the patient. In a previous study, the NCI Surgery Branch used the anti-ESO-1 gene and a type
of virus (retrovirus) to make these tumor-fighting cells (anti-ESO-1 cells). About half of
the patients who received this treatment experienced shrinking of their tumors. In this
study, we are using a slightly different method of producing the anti-ESO-1 cells selected
for a specific cell type, which we hope, will be better in making the tumors shrink.
Objectives:
The purpose of this study is to see if these tumor fighting cells (genetically modified
cells) that express the receptor for the ESO-1 molecule on their surface can cause melanoma
tumors to shrink and to see if this treatment is safe.
Eligibility:
-Adults 18 and older with cancer that has the ESO-1 molecule on tumor surfaces
Design:
- Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and
undergo a history and physical examination, scans, x-rays, lab tests, and other tests
as needed
- Leukapheresis: If the patients meet all of the requirements for the study they will
undergo leukapheresis to obtain white blood cells to make the anti ESO-1 cells.
{Leukapheresis is a common procedure, which removes only the white blood cells from the
patient.}
- Treatment: Once their cells have grown, the patients will be admitted to the hospital
for the conditioning chemotherapy, the anti-ESO 1 cells and aldesleukin. They will stay
in the hospital for about 4 weeks for the treatment.
Follow up: Patients will return to the clinic for a physical exam, review of side effects,
lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1
year as long as their tumors are shrinking. Follow up visits take up to 2 days.
Background:
- A T cell receptor (TCR) that recognizes the NY-ESO-1 (ESO) tumor/testes antigen has
been cloned into a retrovirus and can be used to genetically modify human peripheral
blood lymphocytes (PBL) so they recognize HLA-A2+, ESO+ tumors
- PBL expressing the anti-ESO TCR have been administered with aldesleukin with or without
ALVAC vaccine to 21 patients with melanoma following lymphodepleting chemotherapy at
the Surgery Branch, resulting in objective tumor regression (complete or partial
regression) in ten patients (47%).
- In animal models using murine cells and in experiments with human T cells in vitro, T
cell subsets expressing the lymphoid homing and differentiation marker CD62L, including
na(SqrRoot) ve T cells (TNaive), stem cell memory T cells (TSCM), and central memory T
cells (TCM), were shown to have superior attributes compared to whole PBL and CD62L-
PBL for adoptive cell therapy, including superior persistence following transfer in
vivo.
Objectives:
Primary objective:
- To determine whether the administration of anti-ESO TCR engineered CD62L+-derived
lymphocytes plus high-dose aldesleukin following a non-myeloablative lymphodepleting
preparative regimen can result in an objective regression rate (PR + CR) of melanoma tumors.
Secondary objectives:
- Determine the persistence of genetically engineered, adoptively transferred CD62L+
derived lymphocytes.
- Determine the toxicity profile of this treatment regimen.
Eligibility:
Patients who are:
- HLA-A*0201 positive
- 18 years of age or older
- Have metastatic melanoma that expresses the ESO antigen
Patients may not have:
- Contraindications for high dose aldesleukin administration.
Design:
- PBMC will be obtained by leukapheresis and will undergo positive selection for CD62L
using a CliniMACS magnetic cell separation apparatus to enrich for the less
differentiated TNaive, TSCM, and TCM subsets.
- The enriched CD62L+ lymphocytes will be cultured in the presence of anti-CD3 (OKT3) and
aldesleukin in order to stimulate T-cell growth, then transduced with the anti-ESO TCR.
- All patients will receive a non-myeloablative lymphocyte depleting preparative regimen
of cyclophosphamide and fludarabine.
- On day 0 patients will receive anti-ESO TCR gene-transduced CD62L+ -derived lymphocytes
and then begin high dose aldesleukin.
- A complete evaluation of evaluable lesions will be conducted 6 weeks (+/- 2 weeks)
following the administration of the cell product.
- The primary objective will be efficacy. The study will be conducted using a phase II
optimal design (Simon R, Controlled Clinical Trials 10:1-10, 1989) in order to rule out
an unacceptably low 40% overall response rate (p0=0.40) in favor of an improved
response rate of 65% (p1=0.65). This study will initially enroll 11 evaluable patients,
and if 0 to 5 of the 11 have a response, then no further patients will be accrued. If 6
or more of the first 11 patients have a response, then accrual would continue until a
total of 20 patients have been enrolled. If there were 11 or more responses in 20
patients (55%), this would be sufficiently interesting to warrant further study in
later trials. To allow for a very small number of inevaluable patients, the accrual
ceiling will be set at 22 patients.
- A T cell receptor (TCR) that recognizes the NY-ESO-1 (ESO) tumor/testes antigen has
been cloned into a retrovirus and can be used to genetically modify human peripheral
blood lymphocytes (PBL) so they recognize HLA-A2+, ESO+ tumors
- PBL expressing the anti-ESO TCR have been administered with aldesleukin with or without
ALVAC vaccine to 21 patients with melanoma following lymphodepleting chemotherapy at
the Surgery Branch, resulting in objective tumor regression (complete or partial
regression) in ten patients (47%).
- In animal models using murine cells and in experiments with human T cells in vitro, T
cell subsets expressing the lymphoid homing and differentiation marker CD62L, including
na(SqrRoot) ve T cells (TNaive), stem cell memory T cells (TSCM), and central memory T
cells (TCM), were shown to have superior attributes compared to whole PBL and CD62L-
PBL for adoptive cell therapy, including superior persistence following transfer in
vivo.
Objectives:
Primary objective:
- To determine whether the administration of anti-ESO TCR engineered CD62L+-derived
lymphocytes plus high-dose aldesleukin following a non-myeloablative lymphodepleting
preparative regimen can result in an objective regression rate (PR + CR) of melanoma tumors.
Secondary objectives:
- Determine the persistence of genetically engineered, adoptively transferred CD62L+
derived lymphocytes.
- Determine the toxicity profile of this treatment regimen.
Eligibility:
Patients who are:
- HLA-A*0201 positive
- 18 years of age or older
- Have metastatic melanoma that expresses the ESO antigen
Patients may not have:
- Contraindications for high dose aldesleukin administration.
Design:
- PBMC will be obtained by leukapheresis and will undergo positive selection for CD62L
using a CliniMACS magnetic cell separation apparatus to enrich for the less
differentiated TNaive, TSCM, and TCM subsets.
- The enriched CD62L+ lymphocytes will be cultured in the presence of anti-CD3 (OKT3) and
aldesleukin in order to stimulate T-cell growth, then transduced with the anti-ESO TCR.
- All patients will receive a non-myeloablative lymphocyte depleting preparative regimen
of cyclophosphamide and fludarabine.
- On day 0 patients will receive anti-ESO TCR gene-transduced CD62L+ -derived lymphocytes
and then begin high dose aldesleukin.
- A complete evaluation of evaluable lesions will be conducted 6 weeks (+/- 2 weeks)
following the administration of the cell product.
- The primary objective will be efficacy. The study will be conducted using a phase II
optimal design (Simon R, Controlled Clinical Trials 10:1-10, 1989) in order to rule out
an unacceptably low 40% overall response rate (p0=0.40) in favor of an improved
response rate of 65% (p1=0.65). This study will initially enroll 11 evaluable patients,
and if 0 to 5 of the 11 have a response, then no further patients will be accrued. If 6
or more of the first 11 patients have a response, then accrual would continue until a
total of 20 patients have been enrolled. If there were 11 or more responses in 20
patients (55%), this would be sufficiently interesting to warrant further study in
later trials. To allow for a very small number of inevaluable patients, the accrual
ceiling will be set at 22 patients.
-INCLUSION CRITERIA:
1. Measurable metastatic melanoma that expresses ESO as assessed by one of the following
methods: RT-PCR on tumor tissue, or by immunohistochemistry of resected tissue, or
serum antibody reactive with ESO.
2. Confirmation of diagnosis of metastatic melanoma by the Laboratory of Pathology of
the NCI.
3. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
asymptomatic are eligible. Lesions that have been treated with stereotactic
radiosurgery must be clinically stable for 1 month after treatment for the patient to
be eligible. Patients with surgically resected brain metastases are eligible.
4. Greater than or equal to 18 years of age and less than or equal to 70 years of age.
5. Willing to sign a durable power of attorney
6. Able to understand and sign the Informed Consent Document
7. Clinical performance status of ECOG 0 or 1
8. Life expectancy of greater than three months
9. Patients must be HLA-A*0201 positive
10. Patients of both genders must be willing to practice birth control from the time of
enrollment on this study and for up to four months after treatment
11. Serology:
- Seronegative for HIV antibody. (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune-competence and thus be less responsive to
the experimental treatment and more susceptible to its toxicities.)
- Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
If hepatitis C antibody test is positive, then patient must be tested for the
presence of antigen by RT-PCR and be HCV RNA negative.
12. Women of child-bearing potential must have a negative pregnancy test because of the
potentially dangerous effects of the treatment on the fetus.
13. Hematology
- Absolute neutrophil count greater than 1000/mm(3) without the support of
filgrastim
- WBC greater than or equal to 3000/mm(3)
- Platelet count greater than or equal 100,000/mm(3)
- Hemoglobin > 8.0 g/dl
14. Chemistry:
- Serum ALT/AST less than or equal to 2.5 times the upper limit of normal
- Serum creatinine less than or equal to 1.6 mg/dl
- Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert
s Syndrome who must have a total bilirubin less than 3.0 mg/dl.
15. More than four weeks must have elapsed since any prior systemic therapy at the time
the patient receives the preparative regimen, and patients toxicities must have
recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).
Note: Patients may have undergone minor surgical procedures within the past 3 weeks,
as long as all toxicities have recovered to grade 1 or less or as specified in the
eligibility criteria in Section 2.1.
16. Six weeks must have elapsed from the time of any antibody therapy that could affect
an anti cancer immune response, including anti-CTLA4 antibody therapy, toat the time
the patient receives the preparative regimen to allow antibody levels to decline.
Note: Patients who have previously received ipilimumab and have documented GI toxicity
must have a normal colonoscopy with normal colonic biopsies.
EXCLUSION CRITERIA:
1. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the treatment on the fetus or infant.
2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).
3. Active systemic infections, coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.
4. Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).
5. Concurrent systemic steroid therapy.
6. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.
7. History of coronary revascularization or ischemic symptoms
8. Documented LVEF of less than or equal to 45%. Testing is required in patients with:
- Clinically significant atrial and/or ventricular arrhythmias including but not
limited to: atrial fibrillation, ventricular tachycardia, second or third degree
heart block
- Age greater than or equal to 60 years old
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
